A recent study published in the Journal of Pediatric Endocrinology and Metabolism has revealed that advanced GLP-1 therapies, including semaglutide and tirzepatide, offer comparable glycemic control while delivering superior weight management benefits compared to metformin in adolescents newly diagnosed with type 2 diabetes.
Youth-onset type 2 diabetes (T2D) progresses rapidly, often leading to early complications in adulthood. While metformin remains the first-line therapy for newly diagnosed pediatric patients, its impact on weight loss is minimal, and its durability in glycemic control is limited. GLP-1–based therapies, already recommended for adults, are gaining traction among younger populations due to their glucose-lowering and weight-reducing effects.
The study employed a retrospective, real-world design, extracting data from electronic medical records of an urban pediatric hospital. Eligible participants were youth with newly diagnosed T2D who received GLP-1 receptor agonists (GLP-1RA) or metformin monotherapy between January 2022 and March 2024. Exclusion criteria included combination therapy, insulin as first-line treatment, and secondary diabetes causes. The primary outcomes were monthly changes in HbA1c and percent BMI within the first year post-diagnosis.
Participants included 125 youths, with 113 on metformin and 12 on GLP-1RA therapy. The most prescribed GLP-1RA was semaglutide, followed by tirzepatide. The GLP-1RA group showed greater BMI reduction compared to the metformin group, with adjusted regression analysis indicating an approximately 1% additional monthly BMI reduction with GLP-1 therapy.
At study completion, 83% of GLP-1RA users and 67% of metformin users achieved the target HbA1c of 48 mmol/mol. Despite comparable glycemic control, GLP-1RA therapy conferred superior weight reduction benefits. Adverse events were limited to gastrointestinal symptoms, consistent with known pharmacological effects. However, the small sample size of the GLP-1RA limits generalizability, and baseline BMI differences may have influenced the outcomes.
The study’s limitations include a small GLP-1RA cohort, baseline imbalances in BMI and sex, and a single-center retrospective design. Larger, multicenter trials with balanced cohorts and extended follow-up are required to confirm effects on HbA1c sustainability, beta-cell preservation, and insulin sensitivity.
